Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 160

1.

Rituximab for children with immune thrombocytopenia: a systematic review.

Liang Y, Zhang L, Gao J, Hu D, Ai Y.

PLoS One. 2012;7(5):e36698. doi: 10.1371/journal.pone.0036698. Epub 2012 May 30. Review.

2.

Systematic review: efficacy and safety of rituximab for adults with idiopathic thrombocytopenic purpura.

Arnold DM, Dentali F, Crowther MA, Meyer RM, Cook RJ, Sigouin C, Fraser GA, Lim W, Kelton JG.

Ann Intern Med. 2007 Jan 2;146(1):25-33. Review.

PMID:
17200219
3.

A multi-centre, single-arm, open-label study evaluating the safety and efficacy of fixed dose rituximab in patients with refractory, relapsed or chronic idiopathic thrombocytopenic purpura (R-ITP1000 study).

Tran H, Brighton T, Grigg A, McRae S, Dixon J, Thurley D, Gandhi MK, Truman M, Marlton P, Catalano J.

Br J Haematol. 2014 Oct;167(2):243-51. doi: 10.1111/bjh.13029. Epub 2014 Jul 11.

PMID:
25041261
4.

Evaluation of children with chronic immune thrombocytopenic purpura and Evans syndrome treated with rituximab.

Gokcebay DG, Tavil B, Fettah A, Yarali N, Azik FM, Tunc B.

Clin Appl Thromb Hemost. 2013 Nov-Dec;19(6):663-7. doi: 10.1177/1076029612451649. Epub 2012 Jul 19.

PMID:
22815318
5.

Long-term follow-up of children with refractory immune thrombocytopenia treated with rituximab.

Matsubara K, Takahashi Y, Hayakawa A, Tanaka F, Nakadate H, Sakai M, Maeda N, Oka T, Ishii E, Bessho F, Morimoto T, Goto H, Hashii Y, Hatakeyama N, Shirahata A, Imaizumi M.

Int J Hematol. 2014 Apr;99(4):429-36. doi: 10.1007/s12185-014-1541-y. Epub 2014 Mar 8.

PMID:
24609717
6.

[Clinical efficacy of lower dose rituximab for chronic refractory immune thrombocytopenic purpura].

Li Y, Wang XM, Mao M, Zhang XY, Fu L, Ai HM, Zhang LX.

Zhonghua Xue Ye Xue Za Zhi. 2012 Mar;33(3):204-6. Chinese.

PMID:
22781608
7.

A pilot randomized trial of adjuvant rituximab or placebo for nonsplenectomized patients with immune thrombocytopenia.

Arnold DM, Heddle NM, Carruthers J, Cook DJ, Crowther MA, Meyer RM, Liu Y, Cook RJ, McLeod A, MacEachern JA, Mangel J, Anderson D, Vickars L, Tinmouth A, Schuh AC, Kelton JG.

Blood. 2012 Feb 9;119(6):1356-62. doi: 10.1182/blood-2011-08-374777. Epub 2012 Jan 5.

8.

Dapsone salvage therapy for adult patients with immune thrombocytopenia relapsed or refractory to steroid and rituximab.

Zaja F, Marin L, Chiozzotto M, Puglisi S, Volpetti S, Fanin R.

Am J Hematol. 2012 Mar;87(3):321-3. doi: 10.1002/ajh.22266. Epub 2011 Dec 21.

9.

Efficacy and safety of rituximab given at 1,000 mg on days 1 and 15 compared to the standard regimen to treat adult immune thrombocytopenia.

Mahévas M, Ebbo M, Audia S, Bonnotte B, Schleinitz N, Durand JM, Chiche L, Khellaf M, Bierling P, Roudot-Thoraval F, Godeau B, Michel M.

Am J Hematol. 2013 Oct;88(10):858-61. doi: 10.1002/ajh.23518. Epub 2013 Sep 3.

10.

Rituximab for immune cytopenia in adults: idiopathic thrombocytopenic purpura, autoimmune hemolytic anemia, and Evans syndrome.

Shanafelt TD, Madueme HL, Wolf RC, Tefferi A.

Mayo Clin Proc. 2003 Nov;78(11):1340-6.

PMID:
14601692
11.

Rituximab chimeric anti-CD20 monoclonal antibody treatment for adult refractory idiopathic thrombocytopenic purpura.

Braendstrup P, Bjerrum OW, Nielsen OJ, Jensen BA, Clausen NT, Hansen PB, Andersen I, Schmidt K, Andersen TM, Peterslund NA, Birgens HS, Plesner T, Pedersen BB, Hasselbalch HC.

Am J Hematol. 2005 Apr;78(4):275-80.

12.

[Clinical study of standard dose of rituximab for the treatment of refractory primary immune thrombocytopenia].

Zhu YC, Wang W, Zhou YH, Wang XM, Wang X, Wang YL, Sun GZ, Hou M.

Zhonghua Xue Ye Xue Za Zhi. 2011 Mar;32(3):163-7. Chinese.

PMID:
21535953
13.

Multiple cycles of rituximab therapy in chronic refractory immune thrombocytopenia: a case report with a 10-year follow-up.

Routy B, Boulassel MR, Spurll GM, Warner MN, Routy JP.

Am J Ther. 2013 Mar-Apr;20(2):219-22. doi: 10.1097/MJT.0b013e318258905e.

PMID:
23466621
14.

Long-term follow-up analysis after rituximab salvage therapy in adult patients with immune thrombocytopenia.

Zaja F, Volpetti S, Chiozzotto M, Puglisi S, Isola M, Buttignol S, Fanin R.

Am J Hematol. 2012 Sep;87(9):886-9. doi: 10.1002/ajh.23272. Epub 2012 Jun 20.

15.

Rituximab before splenectomy in adults with primary idiopathic thrombocytopenic purpura: a meta-analysis.

Auger S, Duny Y, Rossi JF, Quittet P.

Br J Haematol. 2012 Aug;158(3):386-98. doi: 10.1111/j.1365-2141.2012.09169.x. Epub 2012 May 22.

PMID:
22612239
16.

Rituximab therapy for chronic and refractory immune thrombocytopenic purpura: a long-term follow-up analysis.

Garcia-Chavez J, Majluf-Cruz A, Montiel-Cervantes L, Esparza MG, Vela-Ojeda J; Mexican Hematology Study Group..

Ann Hematol. 2007 Dec;86(12):871-7. Epub 2007 Sep 14.

17.

Rituximab in auto-immune haemolytic anaemia and immune thrombocytopenic purpura: a Belgian retrospective multicentric study.

Dierickx D, Verhoef G, Van Hoof A, Mineur P, Roest A, Triffet A, Kentos A, Pierre P, Boulet D, Bries G, Lê PQ, Janssens A, Delannoy A.

J Intern Med. 2009 Nov;266(5):484-91. doi: 10.1111/j.1365-2796.2009.02126.x. Epub 2009 Apr 27.

18.

Efficacy of rituximab in primary immune thrombocytopenia: an analysis of adult pretreated patients from everyday hematological practice.

Červinek L, Černá O, Čaniga M, Konířová E, Hluší A, Šimkovič M, Pospíšil Z, Čermák J, Kozák T, Mayer J, Doubek M.

Int J Hematol. 2012 Nov;96(5):594-9. doi: 10.1007/s12185-012-1206-7. Epub 2012 Oct 26.

PMID:
23099924
19.

Rituximab efficacy in the treatment of children with chronic immune thrombocytopenic purpura.

Ansari Sh, Rostami T, Yousefian S, Kiumarsi A, Miri-Aliabad G, Ramim T.

Pediatr Hematol Oncol. 2014 Sep;31(6):555-62. doi: 10.3109/08880018.2014.930766. Epub 2014 Jul 9.

PMID:
25007304
20.

Rituximab efficacy and safety in adult splenectomy candidates with chronic immune thrombocytopenic purpura: results of a prospective multicenter phase 2 study.

Godeau B, Porcher R, Fain O, Lefrère F, Fenaux P, Cheze S, Vekhoff A, Chauveheid MP, Stirnemann J, Galicier L, Bourgeois E, Haiat S, Varet B, Leporrier M, Papo T, Khellaf M, Michel M, Bierling P.

Blood. 2008 Aug 15;112(4):999-1004. doi: 10.1182/blood-2008-01-131029. Epub 2008 May 7.

Supplemental Content

Support Center